Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy. Matsuno O. Int Arch Allergy Immunol 2024;185:116-123.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Matsuno O. Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy. Int Arch Allergy Immunol 2024;185:116-123.
PMID: 37906985